PMID- 35967398
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20231105
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - The efficiency of convalescent plasma in COVID-19 patients: A systematic review 
      and meta-analysis of randomized controlled clinical trials.
PG  - 964398
LID - 10.3389/fimmu.2022.964398 [doi]
LID - 964398
AB  - The objective of this study was to assess whether convalescent plasma therapy 
      could offer survival advantages for patients with novel coronavirus disease 2019 
      (COVID-19). An electronic search of Pubmed, Web of Science, Embase, Cochrane 
      library and MedRxiv was performed from January 1st, 2020 to April 1st, 2022. We 
      included studies containing patients with COVID-19 and treated with CCP. Data 
      were independently extracted by two reviewers and synthesized with a 
      random-effect analysis model. The primary outcome was 28-d mortality. Secondary 
      outcomes included length of hospital stay, ventilation-free days, 14-d mortality, 
      improvements of symptoms, progression of diseases and requirements of mechanical 
      ventilation. Safety outcomes included the incidence of all adverse events (AEs) 
      and serious adverse events (SAEs). The Cochrane risk-of-bias assessment tool 2.0 
      was used to assess the potential risk of bias in eligible studies. The 
      heterogeneity of results was assessed by I;2 test and Q statistic test. The 
      possibility of publication bias was assessed by conducting Begg and Egger test. 
      GRADE (Grading of Recommendations Assessment, Development and Evaluation) method 
      were used for quality of evidence. This study had been registered on PROSPERO, 
      CRD42021273608. 32 RCTs comprising 21478 patients with Covid-19 were included. 
      Compared to the control group, COVID-19 patients receiving CCP were not 
      associated with significantly reduced 28-d mortality (CCP 20.0% vs control 20.8%; 
      risk ratio 0.94; 95% CI 0.87-1.02; p = 0.16; I(2) = 8%). For all secondary 
      outcomes, there were no significant differences between CCP group and control 
      group. The incidence of AEs (26.9% vs 19.4%,; risk ratio 1.14; 95% CI 0.99-01.31; 
      p = 0.06; I(2) = 38%) and SAEs (16.3% vs 13.5%; risk ratio 1.03; 95% CI 0.87-1.20; 
      p = 0.76; I(2) = 42%) tended to be higher in the CCP group compared to the control 
      group, while the differences did not reach statistical significance. In all, CCP 
      therapy was not related to significantly improved 28-d mortality or symptoms 
      recovery, and should not be viewed as a routine treatment for COVID-19 patients. 
      TRIAL REGISTRATION NUMBER: CRD42021273608. Registration on February 28, 2022. 
      SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, Identifier 
      CRD42022313265.
CI  - Copyright (c) 2022 Qian, Zhang, Ma, Shao, Kang and Tong.
FAU - Qian, Zhenbei
AU  - Qian Z
AD  - Department of Respiratory and Critical Care Medicine, Beijing Institute of 
      Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhang, Zhijin
AU  - Zhang Z
AD  - Department of Respiratory and Critical Care Medicine, Beijing Institute of 
      Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Ma, Haomiao
AU  - Ma H
AD  - Department of Respiratory and Critical Care Medicine, Beijing Institute of 
      Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Shao, Shuai
AU  - Shao S
AD  - Department of Respiratory and Critical Care Medicine, Beijing Institute of 
      Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Kang, Hanyujie
AU  - Kang H
AD  - Department of Respiratory and Critical Care Medicine, Beijing Institute of 
      Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Tong, Zhaohui
AU  - Tong Z
AD  - Department of Respiratory and Critical Care Medicine, Beijing Institute of 
      Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220728
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - *COVID-19/therapy
MH  - Humans
MH  - Immunization, Passive/adverse effects
MH  - Length of Stay
MH  - Respiration, Artificial/methods
MH  - COVID-19 Serotherapy
PMC - PMC9366612
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - antibodies
OT  - convalescent plasma
OT  - mortality
OT  - passive immunization
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/17 06:00
PMCR- 2022/07/28
CRDT- 2022/08/15 03:57
PHST- 2022/06/08 00:00 [received]
PHST- 2022/06/29 00:00 [accepted]
PHST- 2022/08/15 03:57 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/07/28 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.964398 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jul 28;13:964398. doi: 10.3389/fimmu.2022.964398. eCollection 
      2022.